Jove
Visualize
Contact Us

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

357
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
357
Inhalational Anesthetics: Overview01:20

Inhalational Anesthetics: Overview

436
Inhalation anesthetics are drugs that induce general anesthesia upon inhalation. They work by increasing the sensitivity of GABAA receptors or inhibiting NMDA receptors, leading to a decrease in central nervous system activity. The depth of anesthesia can be rapidly adjusted by changing the concentration of the inhaled gas. Some common examples of inhalational anesthetics include volatile liquids like isoflurane, desflurane, sevoflurane and gases like xenon and nitrous oxide. Isoflurane, a...
436
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

546
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
546
Asthma-I: Introduction01:29

Asthma-I: Introduction

2.7K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.7K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

341
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
341

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prescribing trends and environmental impact of prescribed inhaled medicines in Australia.

Chronic respiratory disease·2026
Same author

Inhaled Corticosteroid/Long-Acting β<sub>2</sub>-Agonist Selection for Patients with Moderate-to-Severe Asthma: Considerations for Real-World Practice, A Narrative Review.

Advances in therapy·2026
Same author

The use of precision medicine for asthma.

Frontiers in medicine·2026
Same author

A 21-Practice Evaluation of an Asthma and COPD Quality Improvement Program.

Journal of asthma and allergy·2025
Same author

The CURE Asthma roadmap.

The Medical journal of Australia·2025
Same author

Recovery from COVID-19 may take more than just time.

BMJ open respiratory research·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Aug 19, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.8K

Respiratory inhalers and the environment.

Brett D Montgomery1, John D Blakey2

  • 1MBBS, DCH, FRACGP, MMedSci, Senior Lecturer, University of Western Australia, Crawley, WA; General Practitioner, East Fremantle Medical Centre, East Fremantle, WA.

Australian Journal of General Practice
|December 1, 2022
PubMed
Summary
This summary is machine-generated.

This article examines the environmental footprint of common asthma and COPD inhalers. It explores how healthcare providers can balance effective patient treatment with the need to reduce greenhouse gas emissions from inhaler propellants.

Keywords:
greenhouse gas emissionsasthma managementCOPD treatmentsustainable healthcare

Frequently Asked Questions

More Related Videos

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models
07:56

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models

Published on: November 11, 2020

4.3K
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.8K

Related Experiment Videos

Last Updated: Aug 19, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.8K
Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models
07:56

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models

Published on: November 11, 2020

4.3K
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.8K

Area of Science:

  • Environmental health within respiratory medicine
  • Public health policy regarding pressurised metered-dose inhalers

Background:

No prior work has fully resolved the tension between clinical efficacy and the ecological footprint of respiratory devices. Millions of Australians rely on these tools to manage chronic airway conditions daily. Pressurised metered-dose inhalers dominate primary care prescriptions due to their widespread availability and ease of access. These devices frequently utilize potent greenhouse gases as propellants, raising significant sustainability concerns. That uncertainty drove a need to evaluate the environmental consequences of current prescribing habits. Clinicians often prioritize immediate symptom control without considering the long-term atmospheric impact of specific delivery systems. This gap motivated a closer look at how medical practices influence carbon emissions. Understanding this relationship remains a priority for modern healthcare systems aiming for greener outcomes.

Purpose Of The Study:

The aim of this article is to summarize the environmental challenges posed by common respiratory device propellants. It addresses the significant scale of the problem caused by widespread inhaler usage. The authors seek to provide general practitioners with actionable options to mitigate ecological damage. This work explores how to maintain high-quality patient care while reducing carbon emissions. The study investigates the tension between clinical necessity and environmental sustainability in primary care. It highlights the importance of patient-centered prescribing in the context of chronic airway diseases. The authors intend to guide medical professionals toward more sustainable practices without compromising health outcomes. This effort addresses the need for clear strategies to manage the environmental footprint of essential respiratory medications.

Main Methods:

The review approach synthesizes current data regarding the environmental consequences of common respiratory device usage. Authors analyzed the prevalence of specific delivery systems within primary care settings. The investigation evaluated the intersection of clinical guidelines and ecological sustainability. Researchers assessed the availability of over-the-counter options for patients with chronic airway diseases. The study examined the role of greenhouse gas propellants in modern medical devices. Experts reviewed strategies for general practitioners to lower the carbon footprint of their prescriptions. The analysis focused on balancing patient-centered care with environmental responsibility. This methodology provides a framework for understanding the scale of the issue across the Australian population.

Main Results:

Key findings from the literature indicate that millions of respiratory devices are utilized annually across the country. The data shows that pressurised metered-dose inhalers are the most common prescription choice in primary care. These specific devices contain propellants identified as potent greenhouse gases. The literature suggests that the best device for any individual is one they can use reliably. Findings demonstrate that environmental impact can be considered during the decision-making process for chronic disease management. The research highlights that alternative management strategies can also minimize ecological harm. Results indicate that current prescribing habits significantly influence the total carbon output of respiratory care. The evidence confirms that clinicians have options to mitigate these impacts while maintaining high-quality treatment standards.

Conclusions:

The authors suggest that environmental considerations should inform clinical decisions when selecting appropriate respiratory devices for patients. Practitioners can mitigate ecological damage by carefully choosing delivery systems that align with patient needs. Future advancements in climate-friendly propellants will likely reduce the carbon footprint of these essential medical tools. Management strategies that prioritize disease control also contribute to lowering overall environmental harm. Clinicians must ensure that any alternative device remains effective for the individual user. The primary goal of treatment continues to be the maintenance of high-quality patient care. Balancing sustainability with therapeutic outcomes requires ongoing assessment of available prescribing options. This synthesis implies that small changes in clinical practice can collectively support broader environmental health goals.

The researchers propose that clinicians should weigh environmental impacts alongside therapeutic effectiveness when selecting devices. While pMDIs utilize potent greenhouse gases, the most effective tool remains the one a patient can consistently use as prescribed to manage their chronic condition.

The authors identify pressurised metered-dose inhalers as the primary source of concern due to their reliance on specific propellants. These devices are frequently prescribed in primary care and are also available for purchase over the counter by consumers.

The authors state that maintaining high-quality care is necessary for successful management of respiratory conditions. Clinicians must ensure that any shift in prescribing habits does not compromise the patient's ability to use their medication effectively.

The article utilizes data regarding the annual usage rates of respiratory devices among Australians. This information highlights the scale of the problem, as millions of these units are consumed each year for asthma and COPD management.

The researchers note that the environmental impact of these devices is measured by the potency of the greenhouse gases used as propellants. This phenomenon highlights a conflict between medical necessity and atmospheric sustainability.

The authors propose that until newer, climate-friendly propellants become available, doctors should integrate environmental awareness into their prescribing choices. This approach aims to reduce the carbon footprint of respiratory care without sacrificing patient safety.